
    
      24 participants (equally divided between participants with normal hepatic function and those
      with moderate hepatic impairment (defined by the protocol as a Child-Pugh classification of
      grade B score of 7-9)will be given a single injection of teduglutide (20mg) through
      subcutaneous injection into the abdomen. Blood samples would be taken within 30 minutes of
      dose through 24 hours post-dose. Participants in both groups are matched up by sex, age, BMI,
      and renal function.
    
  